This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Iron Substitution After Upper Gastro-Intestinal Bleeding

This study has been completed.
GCP-unit at Aarhus University Hospital, Aarhus, Denmark
Vifor Pharma
Information provided by (Responsible Party):
Palle Bager, University of Aarhus Identifier:
First received: September 16, 2009
Last updated: April 4, 2013
Last verified: April 2013
The trial is a double-blind randomized trial designed to examine whether compliant iron therapy (intravenous or oral) for 3 months after discharge increases hemoglobin levels more and faster than no treatment - in patients with acute bleeding from upper gastrointestinal tract. The trial will include 126 patients at Aarhus University Hospital. In addition to efficacy assessment quality of life assessment and health economic calculations between the treatments will be compared.

Condition Intervention Phase
Gastrointestinal Hemorrhage Anemia Drug: ferricarboxymaltose Drug: Ferrosulfate Drug: Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Comparison of the Efficacy of Compliant Oral Iron Treatment (FerroDuretter ®) for 3 Months After Discharge Versus Single-dose of Intravenous Iron (Ferinject ®) Before Discharge in Patients With Acute Bleeding From Upper Gastrointestinal Tract. A Double Blinded Randomized Trial

Resource links provided by NLM:

Further study details as provided by Palle Bager, University of Aarhus:

Primary Outcome Measures:
  • haemoglobin [ Time Frame: 13 weeks ]

Secondary Outcome Measures:
  • Quality of life Health economics [ Time Frame: 13 weeks, 6 and 12 months ]

Enrollment: 97
Study Start Date: April 2010
Study Completion Date: April 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Intravenous iron Drug: ferricarboxymaltose
Single dose of maximum 1000 mg ferricarboxymaltose intravenous
Other Name: Ferinject
Active Comparator: Oral iron Drug: Ferrosulfate
200mg daily for 12 weeks
Other Name: FerroDuretter
Placebo Comparator: Isotonic Sodium and placebo tablets Drug: Placebo
100 mg isotonic sodium and 2 placebo tablets daily


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Acute upper gastrointestinal bleeding
  • Anemia

Exclusion Criteria:

  • Liver disease
  • Terminal cancer
  • Kidney disease
  • variceal bleeding
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00978575

Aarhus University Hospital
Aarhus, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
GCP-unit at Aarhus University Hospital, Aarhus, Denmark
Vifor Pharma
Study Chair: Hendrik Vilstrup, Professor Aarhus University Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Palle Bager, Clinical Nurse Specialist, RN, MPH, University of Aarhus Identifier: NCT00978575     History of Changes
Other Study ID Numbers: Iron Gab
Study First Received: September 16, 2009
Last Updated: April 4, 2013

Keywords provided by Palle Bager, University of Aarhus:
Iron treatment
Upper gastrointestinal bleeding

Additional relevant MeSH terms:
Gastrointestinal Hemorrhage
Pathologic Processes
Gastrointestinal Diseases
Digestive System Diseases
Trace Elements
Growth Substances
Physiological Effects of Drugs processed this record on August 22, 2017